ALPAAlpa Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ALPA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 31/100)
- • Revenue growth: -21.4% YoY
- • Profit growth: -23.0% YoY
- • RSI: 41
- • Price vs EMA21: below
Bull case
- • Debt/Equity: 0.01
- • Promoter holding: 57.3%
- • Valuation vs sector: P/E 8.7 vs sector 40.5
- • MACD: bullish
Bear case
- • Revenue growth: -21.4% YoY
- • Profit growth: -23.0% YoY
- • RSI: 41
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -21.4% YoY
- • Profit growth: -23.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.58). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.